CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: Lessons for genotype-phenotype association study design in translational pharmacogenetics

Journal of Psychopharmacology

Volumn 25, Issue 7, 2011, Pages 908-914

  Suzuki, Yutaro ^a   Sugai, Takuro ^a   Fukui, Naoki ^a   Watanabe, Junzo ^a   Ono, Shin ^a   Inoue, Yoshimasa ^b   Ozdemir, Vural ^c   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b MP Technopharma Corporation Technology Department   (Japan)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CYP1A2; CYP2D6; dose dependency; fluvoxamine; genotype phenotype association; personalized medicine; smoking status; translational pharmacogenetics

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; FLUVOXAMINE;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG METABOLISM; EVIDENCE BASED MEDICINE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDIVIDUALIZATION; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PHARMACOGENETICS; PRIORITY JOURNAL; STEADY STATE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; FLUVOXAMINE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; JAPAN; MALE; MENTAL DISORDERS; MIDDLE AGED; MUTATION; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; SMOKING; TRANSLATIONAL RESEARCH;

EID: 80052000638     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110370504     Document Type: Article

References (27)

1. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther. 1994 ; 55: 293-304 (Pubitemid 24183729)
2. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of FLV in human is determined by the polymorphic CYP2D6 and also by the CYP 1A2 activity. Clin Pharmacol Ther. 1996 ; 60: 183-190 (Pubitemid 26348233)
3. Christensen M, Tybring G, Mihara K, Yasui-Furukori N, Carrillo JA, Ramos SI. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002 ; 71: 141-152 (Pubitemid 34271117)
4. Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C.T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007 ; 29: 185-189 (Pubitemid 46716184)
5. Gerstenberg G, Aoshima T, Fukasawa T, et al. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of FLV and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit. 2003 ; 25: 463-468 (Pubitemid 36927978)
6. Glatt SJ, Chandler SD, Bousman CA, et al. Alternatively spliced genes as biomarkers for schizophrenia, bipolar disorder and psychosis: a blood-based spliceome-profiling exploratory study. Curr Pharmacogenomics Person Med. 2009 ; 7: 164-188
7. Haddow JE, Palomaki GE Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Khoury M Little J Burke W, ed. New York: Oxford University Press ; 2003: 217-233.
8. Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry. 1998 ; 31: 199-200 (Pubitemid 28505912)
9. Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophyline disposition. Clin Pharmacol Ther. 1976 ; 19: 546-551
10. Iba MM, Fung J, Pak YW, et al. Dose-dependent up regulation of rat pulmonary, renal, and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding. Drug Metab Dispos. 1999 ; 27: 977-982 (Pubitemid 29409630)
11. Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009 ; 29: 319-326
12. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994 ; 46: 452-429
13. Kasper S, Dötsch M, Kick H, Vieira A, Möller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol. 1993 ; 3: 13-21 (Pubitemid 24089488)
14. Mas S, Lafuente A. Pharmacogenetics strategies: from candidate genes to whole-genome association analysis. exploratory or confirmatory studies?. Curr Pharmacogenomics Person Med. 2009 ; 7: 59-69
15. Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol. 2000 ; 410: 107-120 (Pubitemid 32008137)
16. Nebert DW. Given the complexity of the human genome, can 'personalised medicine' or 'individualised drug therapy' ever be achieved?. Hum Genomics. 2009 ; 3: 299-300
17. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. CYP2D6*10 alleles do not determine plasma FLV concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol. 2003 ; 58: 659-661 (Pubitemid 36363293)
18. Ozdemir V, Husereau D, Hyland S, Samper S, Salleh MZ. Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr Pharmacogenomics Person Med. 2009a ; 7: 225-230
19. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of 'edge effect' and cultivating an ethical bridge between omics innovations and society. OMICS. 2009b ; 13: 43-62
20. Paci D, Ibarreta D. Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Curr Pharmacogenomics Person Med. 2009 ; 7: 284-296
21. Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol. 2001 ; 52: 265-271
22. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on FLV pharmacokinetics in humans. Clin Pharmacol Ther. 1995 ; 58: 399-403
23. Spigset O, Granberg K, Hagg S, Norström A, Dahlqvist R. Relationship between FLV pharmacokinetics and CYP2D6/CYP2C19 polymorphisms. Eur J Clin Pharmacol. 1997 ; 52: 129-133 (Pubitemid 27239597)
24. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995 ; 5: 215-223
25. Suzuki Y, Fukui N, Sawamura K, et al. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol. 2008 ; 28: 325-328
26. Watanabe J, Suzuki Y, Fukui N, et al. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Ther Drug Monit. 2008 ; 30: 705-708
27. Wilde M, Plosker G, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 1993 ; 46: 895-924 (Pubitemid 23329964)